with reteplase than with alteplase, although the incidence of symptomatic intracranial hemorrhage and death were similar in the two groups. but, until now, has not been pursued for a stroke indication, lead investigator Shuya Li, MD, Beijing Tiantan Hospital, Beijing, China, and collaborators wrote.
A previous phase 2 trial suggested better outcomes with two 18-mg doses of reteplase than with two 12-mg doses or with alteplase at a dose of 0.9 mg/kg in patients with acute ischemic stroke. The higher dose of reteplase was not associated with an increased risk for fatal bleeding. The primary safety outcome was symptomatic intracranial hemorrhage within 36 hours after symptom onset. This was observed in 17 of 700 patients in the reteplase group and 14 of 699 of those in the alteplase group .
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: washingtonpost - 🏆 95. / 72 Read more »